Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. Completion of the deal is anticipated towards the
The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. Completion of the deal is anticipated towards the
The framework will enable pharmaceutical partners to access integrated data packages combining system-level testing and performance data for injectable therapies. Aptar Pharma stated that demand for earlier insight
This first-in-class complement inhibitor received the approval through a priority review process after its initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN. Results from
The Department of Health and Social Care (DHSC) will consider the guidance before making any decisions about adjustments to the NHS Meningitis B (MenB) vaccination schedule. This latest
Known as Telix Manufacturing Solutions North Melbourne (TMSNM), the site is described as the country’s first purpose-built facility to combine radiochemistry laboratories, clinical manufacturing, patient dose administration, and
HBM7575/SKB575 is designed to target thymic stromal lymphopoietin (TSLP) as well as an undisclosed antigen. The long-acting antibody uses a dual mechanism of action. It works to block
The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to
IBI355 is an Fc-silent, third-generation anti-CD40L antibody that is expected to advance to Phase II trials for immunoglobulin G4 (IgG4)-related disease. Spero plans to launch a global Phase
The agreement grants Novartis access to Chai Discovery’s latest AI models, including its Chai-3 model, to support antibody discovery efforts across a range of therapeutic targets. The partnership
SBT-77-7101 is described as an autologous CAR-Treg cell therapy currently in Phase I clinical development to treat patients with poly-refractory rheumatoid arthritis (RA). These patients with RA have